Classification
Product TypeIngredient
Product FormCrystalline powder
Industry PositionPharmaceutical excipient (carbohydrate)
Market
Pharmaceutical-grade dextrose in India is supplied primarily by the country’s starch-derivatives (corn wet-milling) industry and is used as an excipient/energy source across pharmaceutical manufacturing and supplement formulations. India has domestic producers of dextrose (including monohydrate and anhydrous forms), while high-spec buyer requirements can also drive selective importing for particular compendial or application needs. Regulatory tightening around pharmaceutical GMP expectations (notably revised Schedule M timelines and inspections) increases the importance of supplier audit readiness, documentation discipline, and quality system maturity for excipient vendors. Demand is anchored by India’s large downstream pharmaceutical manufacturing base and the broad nutraceutical/sports-nutrition segment where dextrose is used as a filler/carrier or carbohydrate source.
Market RoleDomestic producer with export and import flows (mixed market)
Domestic RoleB2B input for pharmaceutical and nutraceutical/supplement manufacturing; also used by IV-fluid and healthcare product manufacturers depending on application grade
Market GrowthNot Mentioned
Specification
Primary VarietyDextrose monohydrate (D-glucose monohydrate)
Physical Attributes- White, odorless crystalline powder with mild sweetness
- Moisture control is important to prevent caking and protect flowability
Compositional Metrics- Compendial identity/purity/strength testing expectations where applicable (assay and related specification parameters per pharmacopoeial standards)
- Water-content related checks distinguish monohydrate vs anhydrous forms
Grades- Pharmaceutical grade (compendial specification-led)
- Food/nutraceutical grade (specification-led, buyer-defined)
Packaging- Moisture-barrier bagging/lining is commonly used to protect powder quality during storage and transport (exact pack formats are supplier-specific).
Supply Chain
Value Chain- Starch feedstock sourcing (often maize-based wet milling in India) → hydrolysis to glucose/dextrose → refining/purification → crystallization → drying/milling → QC testing and COA issuance → bagging → distribution to pharmaceutical and nutraceutical manufacturers
Temperature- Typically shipped and stored at ambient temperature; protect from heat and especially moisture ingress to preserve flow and prevent caking.
Atmosphere Control- Low-humidity, clean storage conditions and sealed packaging are important for powder stability and handling.
Freight IntensityHigh
Transport ModeSea
Risks
Regulatory Compliance HighIndia’s revised Schedule M GMP regime and enforcement activity can disrupt excipient-adjacent supply if facilities are not audit-ready or if downstream pharmaceutical buyers tighten qualification; compliance deadlines and inspections have been publicly communicated, increasing the risk of supplier disqualification or regulatory action for non-compliance.Prefer suppliers with documented quality systems, audit history, and compendial testing capability; require written change-control notifications, full COA packs, and contingency-qualified alternate suppliers.
Logistics MediumBecause dextrose is freight-exposed (bulk-to-value), container-rate volatility, port congestion, or regional disruptions can materially affect lead times and delivered cost for imported or exported pharma-grade dextrose shipments.Contract safety stock and dual-source across domestic Indian and import-qualified suppliers; lock critical lanes during peak seasons and pre-book freight for large-volume programs.
Quality Compliance MediumForm and grade mismatches (monohydrate vs anhydrous; pharma-grade vs food-grade) or incomplete compendial documentation can lead to rejection during incoming QC or audit findings, delaying production in pharmaceutical and supplement plants.Standardize incoming specifications by application, require COA alignment to buyer spec, and implement supplier verification testing on identity and key quality attributes.
FAQ
What is the main regulatory risk that could disrupt pharma-grade dextrose supply in India?A key disruption risk is tighter GMP enforcement under India’s revised Schedule M framework: official communications have described revised requirements and inspection activity, which can lead to supplier disqualification by pharmaceutical buyers or regulatory action if a facility is not audit-ready.
How is pharmaceutical-grade dextrose typically produced by Indian starch-derivative suppliers?It is commonly produced by hydrolyzing starch to glucose/dextrose, followed by refining/purification and crystallization into a white crystalline powder (with monohydrate and anhydrous forms), and then releasing batches based on quality testing and documentation.
Why do Indian pharmaceutical and supplement manufacturers insist on pharmacopoeial specifications and a batch COA for dextrose?Because India recognizes the Indian Pharmacopoeia as an official reference for drug standards, and buyers use compendial/specification conformity plus batch COAs to verify identity, purity, and strength and to support audit and quality-system requirements.